Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: Update 2010;Einsatz intravenöser immunglobuline in der neurologie. Ein evidenzbasierter konsens: Update 2010

Nervenarzt

Volumn 82, Issue 4, 2011, Pages 415-430

  Stangel, M ^a   Gold, R ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Evidence based consensus; Indications; Intravenous immunoglobulins; Neurology; Update 2010

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN;

ALZHEIMER DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; EVIDENCE BASED PRACTICE; HUMAN; MYASTHENIA; NEUROLOGIC DISEASE; NEUROLOGY; POSTPOLIOMYELITIS SYNDROME; REVIEW;

BRAIN DISEASES; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; NERVOUS SYSTEM DISEASES;

EID: 79955774823     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-010-3059-8     Document Type: Review

References (111)

1. Achiron A, Kishner I, Dolev M et al (2004) Effect of intravenous immunoglobulin treatment on pregnancy and post-partum related relapses in multiple sclerosis. J Neurol 251:1133-1137 (Pubitemid 39297212)
2. Achiron A, Kishner I, Sarova-Pinhas I et al (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis. A randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515-1520 (Pubitemid 39350261)
3. Ameratunga R, Sinclair J, Kolbe J (2004) Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol 136:111-113 (Pubitemid 38437772)
4. Arias M, Dapena D, Arias-Rivas S et al (2006) Rasmussen encephalitis in the sixth decade: magnetic resonance image evolution and immunoglobulin response. Eur Neurol 56:236-239 (Pubitemid 44934948)
5. Bakker J, Metz L (2004) Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31:265-267 (Pubitemid 38724824)
6. Ballow M (2007) Safety of IGIV therapy and infusion-related adverse events. Immunol Res 38:122-132
7. Bennett JL, Lam C, Kalluri SR et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617-629
8. Bien CG, Granata T, Antozzi C et al (2005) Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128:454-471 (Pubitemid 40380182)
9. Blaes F, Schmitz K, Tschernatsch M et al (2004) Autoimmune etiology of complex regional pain syndrome (M. Sudeck). Neurology 63:1734-1736 (Pubitemid 39507605)
10. Bradl M, Misu T, Takahashi T et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630-643
11. Bril V, Katzberg H, Donofrio P et al (2009) Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 39:448-455
12. Caress JB, Hobson-Webb L, Passmore LV et al (2009) Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 256:339-342
13. Caro XJ, Winter EF, Dumas AJ (2008) A subset of fibromyalgia patients have findings suggestive of chronic inflammatory demyelinating polyneuropathy and appear to respond to IVIg. Rheumatology 47:208-211 (Pubitemid 351168234)
14. Confavreux C, Hutchinson M, Hours MM et al (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339:285-291 (Pubitemid 28366416)
15. Cree BAC, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270-1272
16. Danieli MG, Calcabrini L, Calabrese V et al (2010) Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev (in press)
17. Dauvilliers Y (2006) Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 60:153-153
18. Dauvilliers Y, Carlander B, Rivier F et al (2002) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905-908
19. Delmont E, Azulay JP, Giorgi R et al (2006) Multifocal motor neuropathy with and without conduction block. A single entity? Neurology 67:592-596 (Pubitemid 44273604)
20. Dodel R, Du Y, Depboylu C et al (2004) Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75:1472-1474 (Pubitemid 39279821)
21. Dodel R, Hampel H, Depboylu C et al (2002) Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease. Ann Neurol 52:253-256 (Pubitemid 34810613)
22. Eftimov F, Winer JB, Vermeulen M et al (2009) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev CD001797
23. Elovaara I, Apostolski S, Doorn P van et al (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15:893-908
24. Farbu E, Rekand T, Vik-Mo E et al (2007) Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blind randomized controlled pilot study. Eur J Neurol 14:60-65 (Pubitemid 46088038)
25. Fazekas F, Lublin FD, Li D et al (2010) Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (in press)
26. Fazekas F, Sorensen PS, Filippi M et al (2005) MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler 11:433-440 (Pubitemid 40984238)
27. Filippi M, Rocca MA, Pagani E et al (2004) European study on intravenous immunoglobulin in multiple sclerosis. Results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol 61:1409-1412
28. Fox RJ, Costello F, Judkins AR et al (2006) Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci 251:17-22 (Pubitemid 44803038)
29. Fronczek R, Verschuuren J, Lammers GJ (2007) Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 254:1607-1608 (Pubitemid 350159905)
30. Fu DC, Montgomery JR (2008) High-dose, rapid-infusion IVIG in postvaccination acute disseminated encephalomyelitis. Neurology 71:294-295
31. Fumal A, Jobe J, Pepin J-L et al (2006) Intravenous immunoglobulins in paraneoplastic brainstem encephalitis with anti-Ri antibodies. J Neurol 253:1360-1361 (Pubitemid 44691564)
32. Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev CD002277
33. Gajdos P, Tranchant C, Clair B et al (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulins. Arch Neurol 62:1689-1693
34. Ghosh A, Busby M, Kennett R et al (2005) A practical definition of conduction block in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 76:1264-1268 (Pubitemid 41208381)
35. Goebel A, Moore A, Weatherall R et al (2003) Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepin: a study protocol. BMC Neurology 3
36. Goebel A, Netal S, Schedel R, Sprotte G (2002) Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 3:119-127
37. Goebel A, Stock M, Deacon R et al (2005) Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol 57:463-464 (Pubitemid 40343974)
38. Gonzalez H, Khademi M, Andersson M et al (2004) Prior poliomyelitis-IvIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150:139-144 (Pubitemid 38481657)
39. Gonzalez H, Sunnerhagen KS, Sjöberg I et al (2006) Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 5:493-500
40. Haas J, Hommes OR (2007) A dose comparison study of IVIg in postpartum relapsing-remitting multiple sclerosis. Mult Scler 13:900-908 (Pubitemid 351540862)
41. Haas J, Maas-Enriquez M, Hartung H-P (2005) Intravenous immunoglobulins in the treatment of relapsing-remitting multiple sclerosis - results of a retrospective multicenter observational study over five years. Mult Scler 11:562-567 (Pubitemid 41387701)
42. Harbo T, Andersen H, Hess A et al (2009) Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 16:631-638
43. Hommes OR, Sorensen PS, Fazekas F et al (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149-1156 (Pubitemid 39296602)
44. Hughes RA, Bouche P, Cornblath DR et al (2006) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 13:326-332
45. Hughes RAC, Donofrio P, Bril V et al (2008) Intravenous immunoglobulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136-144
46. Hughes RAC, Swan AV, Raphaël J-C et al (2007) Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130:2245-2257 (Pubitemid 47327619)
47. Iijima M, Yamamoto M, Hirayama M et al (2005) Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64:1471-1475 (Pubitemid 40570528)
48. Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443-1448
49. Jann S, Bramerio MA, Facchetti D, Sterzi R (2009) Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry 80:70-73
50. Jensen P, Bril V (2008) A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis 9:352-355 (Pubitemid 351416827)
51. Joint Task Force of the EFNS and the PNS (2005) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 10:220-228
52. Joint Task Force of the EFNS and the PNS (2006) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 11:1-8
53. Katz U, Achiron A, Sherer Y, Shoenfeld Y (2007) Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 6:257-259 (Pubitemid 46274552)
54. Kizawa M, Mori K, Iijima M et al (2006) Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 77:967-969 (Pubitemid 44174087)
55. Köller H, Schroeter M, Feischen H et al (2006) Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 253:1505-1506 (Pubitemid 44950287)
56. Langer-Gould A, Huang SM, Gupta R et al (2009) Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 66:958-963
57. Lee H-H, Linker RA, Paulus W et al (2008) Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37:406-409 (Pubitemid 351304803)
58. Leger J-M, Viala K, Cancalon F et al (2008) Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J Neurol Neurosurg Psychiatry 79:93-96
59. Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473-477 (Pubitemid 41186945)
60. Levy Y, Uziel Y, Zandman G et al (2005) Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci 1051:779-786 (Pubitemid 41362802)
61. Mandler RN, Ahmed W, Dencoff JE (1998) Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219-1220 (Pubitemid 28473439)
62. Martinez V, Cohen P, Pagnoux C et al (2008) Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 58:308-317
63. Merkies ISJ, Bril V, Dalakas MC et al (2009) Health- related qualiti-of-life improvements in CIDP with immune globulin IV 10%. The ICE study. Neurology 72:1337-1344
64. Milstone AM, Meyers K, Elia J (2005) Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin Rheumatol 24:394-397 (Pubitemid 41102439)
65. Mori M, Kuwabara S, Fukutake T, Hattori T (2007) Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 68:1144-1146 (Pubitemid 46559850)
66. Morozumi S, Kawagashira Y, Iijima M et al (2009) Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjogren's syndrome. J Neurol Sci 279:57-61
67. Multiple Sklerose Therapie Konsensus Gruppe (2006) Immunmodulatorische Studientherapie der Multiplen Sklerose. Aktuelle Therapie-empfehlungen (September 2006). Nervenarzt 77:1506-1518
68. O'Nuallain B, Acero L, Williams AD et al (2008) Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 47:12254-12256
69. Okada K, Tsuji S, Tanaka K (2007) Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 46:1671-1672 (Pubitemid 350111162)
70. Paul F, Jarius S, Aktas O et al (2007) Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica. PLoS Med 4:133
71. Phuphanich S, Brock C (2007) Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol 81:67-69 (Pubitemid 44963991)
72. Piepers S, Van den Berg-Vos R, Van der Pol W-L et al (2007) Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized controlled trial. Brain 130:2004-2010 (Pubitemid 47236626)
73. Pöhlau D, Przuntek H, Sailer M et al (2007) Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 13:1107-1117 (Pubitemid 351541414)
74. Pradhan S, Gupta RP, Shashank S, Pandey N (1999) Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 165:56-61 (Pubitemid 29298082)
75. Rajabally YA, Seow H, Abbott RJ (2007) Immunoglobulin-responsive dysautonomia in Sjogren's syndrome. J Neurol 254:674-675
76. Rajabally YA, Seow H, Wilson P (2006) Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 11:325-329 (Pubitemid 44730223)
77. Ravaglia S, Ceroni M, Moglia A et al (2004) Post-infectious and post-vaccinal acute disseminated encephalomyelitis occurring in the same patients J Neurol 251:1147-1150
78. Ravaglia S, Piccolo G, Ceroni M et al (2007) Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. J Neurol 254:1518-1523 (Pubitemid 350159893)
79. Relkin NR, Szabo P, Adamiak B et al (2010) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (in press)
80. Roed HG, Langkilde A, Sellebjerg FT et al (2005) A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64:804-810 (Pubitemid 40316316)
81. Rüegg SJ, Fuhr P, Steck AJ (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63:2178-2179 (Pubitemid 39636279)
82. Saito E, Koike T, Hashimoto H et al (2008) Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol 18:34-44
83. Schleinitz N, Jean E, Benarous L et al (2008) Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis? Clin Rheumatol 27:1067-1068
84. Shibata-Hamaguchi A, Samuraki M, Furui E et al (2007) Long-term effect of intravenous immunoglobulin on anti-MuSK antibodypositive myasthenia gravis. Acta Neurol Scand 116:406-408 (Pubitemid 350045493)
85. Siegel JM, Boehmer LN (2006) Narcolepsy and the hypocretin system - where motion meets emotion. Nat Clin Pract Neurol 2:548-556 (Pubitemid 44458076)
86. Skeie GO, Apostolski S, Evoli A et al (2006) Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 13:691-699 (Pubitemid 44139369)
87. Slee M, Selvan A, Donaghy M (2007) Multifocal motor neuropathy. The diagnostic spectrum and response to treatment. Neurology 69:1680-1687
88. Sorensen PS, Haas J, Sellebjerg F et al (2004) IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63:2028-2033 (Pubitemid 39636247)
89. Sparks S, Rakocevic G, Joe G et al (2007) Intravenous immune globuline in hereditary inclusion body myopathy: a pilot study. BMC Neurology 7:3
90. Stangel M, Gold R (2004) Einsatz von i.v. Immunglobulinen in der Neurologie. Ein evidenzbasierter Konsens. Nervenarzt 75:801-815
91. Stangel M, Gold R (2005) Hochdosierte intravenöse Immunglobuline in der Behandlung der Multiplen Sklerose. Update über neue Studien. Nervenarzt 76:1267-1272 (Pubitemid 41436254)
92. Stieglbauer K, Topakian R, Hinterberger G, Aichner FT (2009) Beneficial effect of rituximab monotherapy in multifocal motor neuropathy. Neuromuscul Disord 19:473-475
93. Strigl-Pill N, König A, Schröder M et al (2006) Prediction of response to IVIg treatment in patients with lower motor neurone disorders. Eur J Neurol 13:135-140
94. Stüve O, Nessler S, Hartung HP et al (2005) Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment and prognosis. Nervenarzt 76:701-707
95. Tackenberg B, Jelcic I, Baerenwaldt A et al (2009) Impaired inhibitory Fcaγ receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci 106:4788-4792
96. Tackenberg B, Lünemann JD, Steinbrecher A et al (2007) Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 68:1622-1629 (Pubitemid 46717989)
97. Takahashi H, Kawaguchi N, Hattori N (2006) High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive, seronegative myasthenia gravis. J Neurol Sci 247:239-241 (Pubitemid 44301266)
98. Terenghi F, Cappellari A, Bersano A et al (2004) How long is IVIg effective in multifocal motor neuropathy? Neurology 62:666-668
99. Tselis A, Perumal J, Caon C et al (2008) Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulins. Eur J Neurol 15:1163-1167
100. Unay B, Sarici SU, Bulakbasi N et al (2004) Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis associated with hepatitis A infection. Pediatr Int 46:171-173 (Pubitemid 38526612)
101. Valko PO, Khatami R, Baumann CR, Bassetti CL (2008) No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 255:1900-1903
102. Van Koningsveld R, Schmitz PIM, Meché FGA van der et al (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363:192-196 (Pubitemid 38114716)
103. Vedeler CA, Antoine JC, Giometto B et al (2006) Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 13:682-690 (Pubitemid 44139368)
104. Viala K, Renie L, Maisonobe T et al (2004) Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 127:2010-2017 (Pubitemid 39150259)
105. Visser LH, Beekman R, Tijssen CC et al (2004) A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10:89-91 (Pubitemid 38100534)
106. Voltz R (2006) Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol 253(Suppl 5):33-38
107. Vucic S, Black KR, Siao Tick Chong P, Cros D (2004) Multifocal motor neuropathy. Decrease in conduction block and reinnervation with long-term IVIg. Neurology 63:1264-1269
108. Wakasugi D, Kato T, Gono T et al (2009) Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjogren's syndrome. Mod Rheumatol 19:437-440
109. Warrington AE, Bieber AJ, Ciric B et al (2007) A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res 85:967-976 (Pubitemid 46580338)
110. Weinstock-Guttman B, Ramanathan M, Lincoff N et al (2006) Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 63:957-963 (Pubitemid 44036296)
111. Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial. Neurology 68:837-841